Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Has Average Price Target of $61.92

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $61.92.

Several research firms have recently weighed in on CLDX. Guggenheim raised their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Stifel Nicolaus set a $68.00 price objective on Celldex Therapeutics in a report on Tuesday, September 22nd. Cantor Fitzgerald upped their target price on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 22nd. Morgan Stanley increased their price target on Celldex Therapeutics from $50.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, September 23rd. Finally, Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $29.89 on Friday. Celldex Therapeutics has a 12-month low of $22.10 and a 12-month high of $45.14. The firm has a 50-day moving average price of $37.74 and a 200 day moving average price of $34.93. The firm has a market capitalization of $2.35 billion, a PE ratio of -6.87 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. On average, research analysts expect that Celldex Therapeutics will post -4.17 EPS for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors have recently modified their holdings of the business. Handelsbanken Fonder AB lifted its stake in Celldex Therapeutics by 5.0% in the second quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 1,300 shares in the last quarter. Nykredit A S bought a new stake in Celldex Therapeutics during the 2nd quarter worth about $67,000. Arizona State Retirement System boosted its position in Celldex Therapeutics by 13.0% during the second quarter. Arizona State Retirement System now owns 18,565 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 2,139 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Celldex Therapeutics by 3.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 77,772 shares of the biopharmaceutical company’s stock valued at $2,467,000 after buying an additional 2,642 shares during the last quarter. Finally, Mirador Capital Partners LP lifted its stake in Celldex Therapeutics by 1.7% in the second quarter. Mirador Capital Partners LP now owns 181,054 shares of the biopharmaceutical company’s stock valued at $6,737,000 after acquiring an additional 3,001 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.